Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Daily News

Method Chosen to Estimate Pre-PCI Kidney Function Matters

L.A. McKeown

June 29, 2015

News Daily News

African Americans’ Antiplatelet Response Handicapped by Gene Variant, ‘Race’

June 07, 2013

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

Advertisement

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Method Chosen to Estimate Pre-PCI Kidney Function Matters

African Americans’ Antiplatelet Response Handicapped by Gene Variant, ‘Race’

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content